Norwegian Surveillance System for Communicable Diseases (Norway)

Database Contact Data

Christina Bergland
Executive Director, Division of Health Data and Digitalisation
Norwegian Institute of Public Health
NORWAY
Email: Christine.Bergland@fhi.no

Alternate Contact

For data access, send an email to datatilgang@fhi.no

General contact information for MSIS -
Phone: (+47) 2107 7000

References of Studies Using/Describing Database

1. Tipu JH, Sivertsen A, Afset JE, Sandven L, Brekke H, Lund HM, Elburg LS, Gaustad P, Lier T, Tverelv LR, Johansen ØH. Cryptosporidium species and subtypes in Norway: predominance of C. parvum and emergence of C. mortiferum. Emerging Microbes & Infections. 2024 Dec 31;13(1):2412624.

2. Tunheim G, Fossum E, Robertson AH, Rø GØ, Chopra A, Vaage JT, Vikse EL, Kran AM, Magnus P, Trogstad L, Mjaaland S. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults. BMC Infectious Diseases. 2024 Aug 20;24(1):841.

3. Trinh NT, Houghtaling J, Bernal FL, Hayati S, Maglanoc LA, Lupattelli A, Halvorsen L, Nordeng HM. Harmonizing Norwegian registries onto OMOP common data model: Mapping challenges and opportunities for pregnancy and COVID-19 research. International Journal of Medical Informatics. 2024 Aug 14:105602.

4. Salamanca BV, Cyr PR, Bentdal YE, Watle SV, Wester AL, Strand ÅM, Bøås H. Increase in invasive group A streptococcal infections (iGAS) in children and older adults, Norway, 2022 to 2024. Eurosurveillance. 2024 May 16;29(20):2400242.

5. Jore S, Viljugrein H, Hjertqvist M, Dub T, Mäkelä H. Outdoor recreation, tick borne encephalitis incidence and seasonality in Finland, Norway and Sweden during the COVID-19 pandemic (2020/2021). Infection Ecology & Epidemiology. 2023 Dec 31;13(1):2281055.

6. Hetlevik Ø, Wensaas KA, Baste V, Emberland KE, Özgümüs T, Håberg SE, Rortveit G. Prevalence and predictors of post-COVID-19 symptoms in general practice-a registry-based nationwide study. BMC Infectious Diseases. 2023 Oct 25;23(1):721.

7. Gravningen K, Nymark P, Wyller TB, Kacelnik O. A new automated national register-based surveillance system for outbreaks in long-term care facilities in Norway detected three times more severe acute respiratory coronavirus virus 2 (SARS-CoV-2) clusters than traditional methods. Infection Control & Hospital Epidemiology. 2023 Sep;44(9):1451-7.

8. Whittaker R, Toikkanen S, Dean K, Lyngstad TM, Buanes EA, Kløvstad H, Paulsen TH, Seppälä E. A comparison of two registry-based systems for the surveillance of persons hospitalised with COVID-19 in Norway, February 2020 to May 2022. Eurosurveillance. 2023 Aug 17;28(33):2200888.

9. Caspersen IH, Trogstad L, Galanti MR, Karvonen S, Peña S, Shaaban AN, Håberg SE, Magnus P. Current tobacco use and SARS-CoV-2 infection in two Norwegian population-based cohorts. BMC Public Health. 2023 May 10;23(1):846.

10. Skagseth H, Jørgensen SB, Reilly J, Kacelnik O. A new method for near real-time, nationwide surveillance of nosocomial COVID-19 in Norway: providing data at all levels of the healthcare system, March 2020 to March 2022. Eurosurveillance. 2023 Mar 23;28(12):2200493.

Apr 26, 2023: Learn all about the Icelandic Register of Communicable Diseases

Starting in 1997, the Icelandic Register of Communicable Diseases includes diseases, agents causing diseases and events, immunisations, and use of antimicrobial drugs, and is intended to be of use in preventive measures and in epidemiological research. Notifiable communicable diseases which can pose a threat to public welfare are subject to registration.

Icelandic Register of Communicable Diseases (Iceland)

Database Contact Data

Sigríður Haralds Elínardóttir
Head of Division, Health Information
Directorate of Health
Katrínartún 2 
IS – 105 Reykjavík
ICELAND
Phone: +354 510 1900
Email: sigridur.haraldsd.elinardottir@landlaeknir.is

Alternate Contact

Directorate of Health
Katrínartún 2
105 Reykjavík
Kt. 710169-5009
ICELAND
Tel: + 354 510 1900
E-mail: mottaka@landlaeknir.is

References of Studies Using/Describing Database

N/A

Apr 19, 2023: Were you aware that DGI offers some discounts all year round?

Academia / Nonprofits / Government agencies always get a discounted rate, as do companies that let us profile their population healthcare databases/registries in our resource. In addition, if you sign up for Unlimited Users worldwide for 2 or more years, you can receive a 10% discount (pre-paid)! Finally, licensing our B.R.I.D.G.E.

Apr 11, 2023: We welcome NCRAS, our newest cancer registry from the United Kingdom

With registrations starting back in 1948, the National Cancer Registration and Analysis Service (NCRAS) is run by the National Disease Registration Service (NDRS) which is part of NHS England. It is responsible for cancer registration in England to support cancer epidemiology, public health, service monitoring and research. NCRAS is responsible for systematic collection of data about cancer and tumour diseases in England.

National Cancer Registration and Analysis Service (NCRAS) (United Kingdom)

Database Contact Data

Sarah Stevens
Associate Director for NDRS
(National Disease Registration Service)
Email: sarah.stevens1@nhs.net

Alternate Contact

N/A

References of Studies Using/Describing Database

1. White BE, Russell B, Remmers S, Rous B, Chandrakumaran K, Wong KF, Van Hemelrijck M, Srirajaskanthan R, Ramage JK. Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012-2018: A Retrospective, Population-Based Study. Cancers (Basel). 2023 Mar 20;15(6):1863. 

2. Sundar S, Nordin A, Morrison J, Wood N, Ghaem-Maghami S, Nieto J, Phillips A, Butler J, Burton K, Gornall R, Dobbs S, Glasspool R, Peevor R, Ledermann J, McNeish I, Ratnavelu N, Duncan T, Frost J, Lim K, Michael A, Brockbank E, Gajjar K, Taylor A, Bowen R, Andreou A, Ganesan R, Nicum S, Edmondson R, Clayton R, Balega J, Rolland P, Maxwell H, Fotopoulou C. British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer. Cancers (Basel). 2023 Jan 4;15(2):337.

3. Paisey SA, Weerasuriya S, Palmer K, White BE, Srirajaskanthan R, Chandrakumaran K, Ramage JK. Primary renal neuroendocrine neoplasms: A systematic literature review, report of four local cases, and original survival analysis of 63 patients from a national registry 2012-2018. J Neuroendocrinol. 2022 Dec;34(12):e13215.

4. M A, S C, J F, C L, A B, L P, Sj S. Incidence and Outcome of Breast Sarcomas in England (2013-2018): An analysis from the National Cancer Registration and Analysis Service. Eur J Cancer. 2022 Oct;174:48-56. 

5. White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, George G, Russell B, Srirajaskanthan R, Ramage JK. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study. Lancet Reg Health Eur. 2022 Sep 23;23:100510. 

6. Aggarwal A, Han L, van der Geest S, Lewis D, Lievens Y, Borras J, Jayne D, Sullivan R, Varkevisser M, van der Meulen J. Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study. Lancet Oncol. 2022 Sep;23(9):1211-1220. 

7. Ng OH, Lunevicius R, Arthur JD. Rising incidence of colorectal cancer in individuals younger than 50 years and increasing mortality from rectosigmoid cancer in England. Colorectal Dis. 2021 Oct;23(10):2637-2646.

8. Wanis HA, Møller H, Ashkan K, Davies EA. The incidence of major subtypes of primary brain tumors in adults in England 1995-2017. Neuro Oncol. 2021 Aug 2;23(8):1371-1382.

9. Lai J, Mak V, Bright CJ, Lyratzopoulos G, Elliss-Brookes L, Gildea C. Reviewing the impact of 11 national Be Clear on Cancer public awareness campaigns, England, 2012 to 2016: A synthesis of published evaluation results. Int J Cancer. 2021 Mar 1;148(5):1172-1182. 

10. Burton A, Tataru D, Driver RJ, Bird TG, Huws D, Wallace D, Cross TJS, Rowe IA, Alexander G, Marshall A; HCC-UK/BASL/NCRAS Partnership Steering Group. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep. 2021 Jan 19;3(2):100232.

Apr 4, 2023 – Now uploaded - National Surveillance System profile from Canada

With data starting in 2003, the National Ambulatory Care Reporting System (NACRS) provides valuable insights into emergency department (ED) visits and lengths of stay reported by participating provinces and territories in Canada. NACRS collects demographic, administrative, clinical and service-specific data for ED, day surgery and other ambulatory care visits.

National Ambulatory Care Reporting System (NACRS) (Canada)

Database Contact Data

Email: help@cihi.ca
Phone: +1 613-241-5543

Alternate Contact

1. CIHI publishes a wealth of publicly available statistics (see https://www.cihi.ca/en/access-data-and-reports).

2. If you’re looking for more detailed information, you can make a custom data request by using their Data Inquiry Form at https://www.cihi.ca/en/data-inquiry-form.

References of Studies Using/Describing Database

1. Burgesson B, Lethbridge L, Haase D, Dunbar M; Published in collaboration with the Health Association of African Canadians. Disparities in Utilization Rates of Total Knee and Hip Arthroplasty Among Racially Visible Populations in Canada: A Retrospective Cohort Analysis. J Arthroplasty. 2025 Apr 11:S0883-5403(25)00336-5.

2. Dick K, Kaczmarek E, Ducharme R, Bowie AC, Dingwall-Harvey ALJ, Howley H, Hawken S, Walker MC, Armour CM. Transformer-based deep learning ensemble framework predicts autism spectrum disorder using health administrative and birth registry data. Sci Rep. 2025 Apr 7;15(1):11816.

3. Yin CY, Scott MM, Talarico R, Hakimjavadi R, Kierulf J, Webber C, Hawken S, Moledina A, Manuel D, Hsu A, Tanuseputro P, Fung C, Kaasalainen S, Molnar F, Shamon S, McIsaac DI, Kobewka D. Transfer from long-term care to acute care and risk of new permanent cognitive or physical disability among long-term care residents in Canada: protocol for a retrospective cohort study. BMJ Open. 2025 Jan 20;15(1):e086932.

4. Yao X, Champagne AS, McFaull SR, Thompson W. Temporal trends and characteristics of fall-related deaths, hospitalizations and emergency department visits among older adults in Canada. Health Promot Chronic Dis Prev Can. 2024 Nov;44(11-12):482-487.

5. Mirzadeh P, Kuk JL, Wharton S, Reid RA, Ardern CI. Healthcare outcomes and dispositions in persons with obesity within emergency departments in Ontario, Canada: A cross-sectional analysis of the National Ambulatory Care Reporting System (NACRS), 2018-2022. PLoS One. 2024 Sep 26;19(9):e0311190.

6. Khalid A, Muchaal PK, Julien DA. Human echinococcosis incidence in Canada: A retrospective descriptive study using administrative hospital and ambulatory visit data, 2000-2020. Can Commun Dis Rep. 2024 Sep 5;50(9):305-311.

7. Dengler J, Perlman M, Jennett M, Marcon E, Guilcher S. An Examination of Utilization Rates Over Time of Nerve and Tendon Transfers in Canada to Improve Upper Limb Function in Cervical Spinal Cord Injury. Plast Surg (Oakv). 2024 Aug;32(3):367-373.

8. Brissette V, Kapral MK, Yu B, Fang J, Odugbemi T, Shamy M, Fahed R, Dowlatshahi D, Gocan S, Martineau I. Seasonal Variations in Stroke Occurrence. Neuroepidemiology. 2024 Jul 22:1-10.

9. Ferro MA, Chan CKY, Browne DT, Colman I, Dubin JA, Duncan L. Suicidal Ideation and Attempts Among Youth With Physical-Mental Comorbidity in Canada: Proposal for an Epidemiological Study. JMIR Res Protoc. 2024 Jul 4;13:e57103.

10. Benny C, Hobin E, Andreacchi AT, Schwartz N, Smith BT. Socio-economic inequities in emergency department visits for wholly alcohol-attributable acute and chronic harms in Canada, 2003-2017. Drug Alcohol Rev. 2024 May;43(4):927-936.

Mar 30, 2023: Introducing BADBIR, a UK psoriasis registry

The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a national register of all patients receiving biologic therapy for the treatment of psoriasis in the United Kingdom. The National Institute for Health and Clinical Excellence (NICE) has recommended that all patients in the UK receiving these new therapies for Psoriasis should be registered in BADBIR. BADBIR has grown to be the largest psoriasis study of its kind globally.

Subscribe to